Details

Autor(en) / Beteiligte

• Büller, Harry R
• Prins, Martin H
• Lensin, Anthonie W A
• Decousus, Hervé
• Jacobson, Barry F
• Minar, Erich
• Chlumsky, Jaromir
• Verhamme, Peter
• Wells, Phil
• Agnelli, Giancarlo
• Cohen, Alexander
• Berkowitz, Scott D
• Bounameaux, Henri
• Davidson, Bruce L
• Misselwitz, Frank
• Gallus, Alex S
• Raskob, Gary E
• Schellong, Sebastian
• Segers, Annelise

Titel

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

Ist Teil von

• The New England journal of medicine, 2012-04, Vol.366 (14), p.1287-1297

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• In the treatment of patients with acute pulmonary embolism, the efficacy of rivaroxaban, a factor Xa inhibitor, was similar to that of traditional anticoagulation therapy. There was less bleeding in the group receiving rivaroxaban, which supports its use in the treatment of this condition. Pulmonary embolism is a common disease, with an estimated annual incidence of 70 cases per 100,000 population. 1 , 2 The condition usually leads to hospitalization and may recur; it can be fatal. 3 For half a century, the standard therapy for most patients with pulmonary embolism has been the administration of heparin, overlapped and followed by a vitamin K antagonist. 4 , 5 This regimen is effective but complex. 5 – 9 Recently developed oral anticoagulants that are directed against factor Xa or thrombin overcome some limitations of standard therapy, including the need for injection and for regular dose adjustments on the basis of laboratory monitoring. . . .